Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 25;26(15):7215.
doi: 10.3390/ijms26157215.

Cardioprotective Role of Captopril: From Basic to Applied Investigations

Affiliations
Review

Cardioprotective Role of Captopril: From Basic to Applied Investigations

Marko Stoiljkovic et al. Int J Mol Sci. .

Abstract

Captopril, a well-established angiotensin-converting enzyme (ACE) inhibitor, has garnered attention for its cardioprotective effects in preventing heart remodeling and maintaining cardiac function, significantly improving life quality. However, recent studies have revealed that in addition to known hemodynamic alterations, captopril exhibits significant antioxidant, anti-inflammatory, and immunomodulatory effects that may underlie its protective mechanisms. Although it appeared to be overlooked in clinical practice, in recent years, additional efforts have been made to uncover the mechanisms of all drug effects, as recent research studies predict a wide spectrum of diseases beyond the recommended indications. This review thoroughly examines the mechanisms by which captopril mediates its protective effects, bridging basic biochemical observations with applied clinical investigation, especially during ischemic reperfusion (I/R) injury, hypertension, and heart failure (HF). Evidence points to captopril as a promising agent for modulating oxidative and inflammatory pathways that are crucial for cardiovascular medicine. Directions for future research are defined to determine the molecular targets of captopril further and to optimize its clinical utility in the management of cardiovascular and possibly other diseases.

Keywords: basic studies; captopril; cardiac remodeling; clinical studies; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Captopril in cardiovascular modulation.

Similar articles

References

    1. Ferreira S.H. A bradykinin-potentiating factor (bpf) present in the venom of Bothrops jararaca. Br. J. Pharmacol. Chemother. 1965;24:163–169. doi: 10.1111/j.1476-5381.1965.tb02091.x. - DOI - PMC - PubMed
    1. Bakhle Y.S. Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung. Nature. 1968;220:919–921. doi: 10.1038/220919a0. - DOI - PubMed
    1. Ferreira S.H., Greene L.J., Alabaster V.A., Bakhle Y.S., Vane J.R. Activity of Various Fractions of Bradykinin Potentiating Factor against Angiotensin I Converting Enzyme. Nature. 1970;225:379–380. doi: 10.1038/225379a0. - DOI - PubMed
    1. Cushman D.W., Ondetti M.A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;17:589–592. doi: 10.1161/01.HYP.17.4.589. - DOI - PubMed
    1. Thind G.S. Angiotensin converting enzyme inhibitors: Comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc. Drugs Ther. 1990;4:199–206. doi: 10.1007/BF01857634. - DOI - PubMed

LinkOut - more resources